THERAVANCE BIOPHARMA INC (TBPH)
KYG8807B1068 - Common Stock
Theravance Biopharma to Participate in an Upcoming Investor Conference
/PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference...
Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024
/PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2024 financial results and provide a business update after market close...
BTIG Research Predicts Over 118% Rally for These 3 Stocks
Wall Street stock predictions can run wild but after the tech sector's gains, these stocks could be better places for your money.
Theravance Biopharma Breaks Above 200-Day Moving Average - Bullish for TBPH
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024
/PRNewswire/ -- Theravance Biopharma, Inc. (the "Company") (NASDAQ: TBPH) today announced it will host a virtual KOL event on Thursday, May 23, 2024 from 10:00...
Short-Squeeze Showdown: 3 Stocks Ready to Crush the Skeptics
Although the bears see cynical opportunities, you can make give them a taste of their own medicine with these short-squeeze stocks.
Theravance Biopharma (TBPH) Shares Cross Above 200 DMA
Theravance Biopharma GAAP EPS of -$0.17 misses by $0.02, revenue of $17.6M beats by $0.03M (NASDAQ:TBPH)
Theravance Biopharma reported Q4 financial results, with a miss on EPS but a beat on revenue.
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
/PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced financial and operational results for the...
Theravance Biopharma to Participate in an Upcoming Investor Conference
/PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in the CNS Corporate Panel Discussion at the TD Cowen 44th Annual Health Care...
Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
/PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2023 financial results and provide a business update...
Theravance Biopharma is Now Oversold (TBPH)
Theravance, Mylan settle Yupelri patent dispute with Orbicular
Theravance Biopharma (TBPH) and Viatris (VTRS) unit, Mylan settle patent dispute over generic Yupelri with Orbicular Pharmaceutical Technologies, Read more here.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Pre-market stock movers are worth checking on Friday as we lay out all of the biggest stories worth keeping tabs on this morning!
Theravance stock drops as late-stage trial for Yupelri fails
Theravance Biopharma (TBPH) stock drops 16% as its lung disorder therapy, Yupelri, fails to meet primary endpoint in Phase 4 trial. Read more here.
Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
/PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced results from the Phase 4 PIFR-2 study of YUPELRI® (revefenacin) inhalation solution,...
7 Short-Squeeze Stocks That Are Screaming for Speculation
If you like to march to your own beat even against high pressure, these short-squeeze stocks could be right for you.
Theravance Biopharma signs cooperation agreement with Irenic Capital (NASDAQ:TBPH)
Theravance Biopharma teams up with activist investor Irenic Capital Management as Jeremy Grant joins board.
Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors
/PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance" or the "Company") (NASDAQ: TBPH) today announced the appointment to its Board of Directors of Jeremy...
Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference
/PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that members of its management team...
Theravance Biopharma to Present New Ampreloxetine Data at the 34th International Symposium on The Autonomic Nervous System
/PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that a new, anchor-based analysis of...
Theravance Biopharma to Participate in the 6th Annual Evercore ISI HealthCONx Conference
/PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference Tuesday,...
TBPH Makes Bullish Cross Above Critical Moving Average
Theravance Biopharma, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update
Q3 2023 YUPELRI® (revefenacin) net sales, recognized by Viatris, increased 9% from Q3 2022, reaching an all-time high of $58.3 million1 Progress made towards...
Theravance, Mylan settle patent litigation over COPD drug Yupelri (TBPH)
Theravance (TBPH) and Mylan (VTRS)have granted Teva (TEVA) a license to market a generic version of their drug Yupelri in the US, settling their patent dispute. Read more here.
Noteworthy Tuesday Option Activity: HE, TBPH, TTD
Theravance Biopharma to Report Third Quarter 2023 Financial Results on November 7, 2023
/PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2023 financial results and provide a business update after market close...